network member

Fred & Pamela Buffett Cancer Center

Omaha, NE
Fred & Pamela Buffett Cancer Center

About Network Member

The Fred & Pamela Buffett Cancer Center became an NCI-designated cancer center in 1999. The mission of the Fred & Pamela Buffett Cancer Center is to coordinate basic and clinical cancer research, patient care, and educational programs, and to facilitate the application of new knowledge about the etiology, diagnosis, treatment, and prevention of cancer. Research at the Fred & Pamela Buffett Cancer Center is conducted in four research programs: cancer genes and molecular regulation program, molecular and biochemical etiology program, gastrointestinal cancer program, and cancer prevention and control program. Notable programs in research include work on lymphoma and bone marrow transplantation, pancreatic cancer, and breast cancer. Clinical care is provided by Nebraska Medicine at multiple locations throughout the area. The Fred & Pamela Buffett Cancer Center is also a member of the National Comprehensive Cancer Network, an alliance that develops standards and sets guidelines for treatment. Multidisciplinary teams conduct research focused on discovering the mechanisms, which cause cancer to develop and then translate these discoveries into new approaches for early detection and new therapies for cancer treatment and prevention. The Fred & Pamela Buffett Cancer Center is partners with the UNMC Department of Pediatrics and Children’s Hospital and Medical Center, which provides enhanced access and increased accrual of children with cancer into clinical trials. The Fred & Pamela Buffett Cancer Center reaches out to the medical community and the broader public through a variety of education and outreach programs for scientists, clinicians, health care workers, future scientists and healthcare providers, and the general public. For example, the Cancer Research Graduate Program trains students in the latest techniques of cancer research, awarding a Ph.D. upon completion. Community outreach programs are educating the public on the importance of cancer prevention and early detection. At several annual events, the Fred & Pamela Buffett Cancer Center provides free cancer screening to Nebraska’s underserved populations. In 2013, as a result of a generous gift from Pamela Buffett through her foundation, the Rebecca Susan Buffett Foundation, ground was broken on a new cancer center complex on the campus shared by the University of Nebraska Medical Center and Nebraska Medicine. The Fred & Pamela Buffett Cancer Center includes a ten story cancer research tower call the Suzanne and Walter Scott Cancer Research Tower, 108 inpatient beds called the C.L. Werner Cancer Hospital, and a multidisciplinary outpatient clinic that includes surgical, medical, and radiation oncology, a 24/7 infusion center, as well as radiology and lab services. The facility opened in June 2017. Website: Fred & Pamela Buffett Cancer Center
Currently Enrolling

HCRN-BRE20-468

A Phase II Study of Ribociclib And Endocrine Treatment of Physician’s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)
Cancer areas:Breast
Fred & Pamela Buffett Cancer Center
New York University Cancer Institute
Orlando Health Cancer Institute
Parkview Research Center
Penn State Cancer Institute
Providence Cancer Institute
Rutgers Cancer Institute of New Jersey
The Ohio State University
Tufts Medical Center
University of Alabama at Birmingham Comprehensive Cancer Center
University of Arizona Cancer Center
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Michigan Health-West
University of Michigan Rogel Cancer Center
University of Virginia Cancer Center
University of Wisconsin Carbone Cancer Center
Currently Enrolling

HCRN-GU16-243

PhAse I/II StuDy of Modern ImmunotherApy in BCG-RelaPsing UroThelial Carcinoma of the BLADDER – (ADAPT-BLADDER) HCRN GU16-243
Columbia University Irving Medical Center
Fox Chase Cancer Center
Fred & Pamela Buffett Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
University of Iowa Holden Comprehensive Cancer Center
Currently Enrolling

BTCRC-LUN18-153

A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
Cancer areas:Lung
Fred & Pamela Buffett Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Masonic Cancer Center, University of Minnesota
Moffitt Cancer Center
Penn State Cancer Institute
Providence Cancer Institute
Rutgers Cancer Institute of New Jersey
The Ohio State University
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Virginia Cancer Center
Virginia Commonwealth University
Enrollment Closed

BTCRC-AML17-113

Phase Ib study of the safety and efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in patients with relapsed or refractory CD33+ acute myeloid leukemia: Big Ten Cancer Research Consortium BTCRC-AML17-113
Cancer areas:Leukemia
Fred & Pamela Buffett Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
University of Illinois Cancer Center
Enrollment Closed

BTCRC-BRE16-042

A Phase II Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients: Big Ten Cancer Research Consortium BTCRC-BRE16-042
Cancer areas:Breast
Fred & Pamela Buffett Cancer Center
Michigan State University
New York University Cancer Institute
Rutgers Cancer Institute of New Jersey
University of Wisconsin Carbone Cancer Center
Enrollment Closed

BTCRC-BRE19-409

A Phase II, Single Arm, Non-randomized Study of Alpelisib (BYL719) in Combination with Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE19-409
Cancer areas:Breast
Fred & Pamela Buffett Cancer Center
Penn State Cancer Institute
University of Illinois Cancer Center
University of Wisconsin Carbone Cancer Center
Enrollment Closed

BTCRC-GI20-457

A Phase II study of Atezolizumab and Bevacizumab in Child-Pugh B7 Hepatocellular Carcinoma (The AB7 Trial) Big Ten Cancer Research Consortium BTCRC-GI20-457
Cancer areas:Liver and Bile Duct
DHR Health
Fred & Pamela Buffett Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
New York University Cancer Institute
Rutgers Cancer Institute of New Jersey
University of Illinois Cancer Center
University of Wisconsin Carbone Cancer Center